Thank you, Tuukka, and welcome to Orion's Q3 webcast on my behalf as well. Nubeqa saavutti myös kaikkien aikojen korkeimmat rojaltit ja tuotelähetykset Bayerille kolmannella neljänneksellä. Availability of products in our mature markets and very successful new launches. Valitettavasti ODM-105 tasipimidine -vaiheen 2 tutkimus unettomuuteen ei saavuttanut tavoitteitaan. Efficacy target, and we decided to discontinue the development of that program. And Q3 financials are here, and before I go deeper into the financials. On hyvä muistaa, että vertailujakso Q3 vuonna 2024 oli poikkeuksellinen neljännes. We received one hundred and thirty million worth of milestones last year. Q3. There was a seventy million sales milestone from Bayer related to Nubeqa® and a sixty million milestone. Liittyen MSD:n ja Opevesostat-sopimukseen on vaikeaa verrata näitä keskenään, ja nyt kun jatkan. I will talk about the base business, which is the business excluding the milestones. The base business growth was twenty-four percent from quarter three last year to this year's quarter three, totaling 423 million in operating profit. Growth was even stronger at sixty-eight percent, up to one hundred and one million euros. Q3. The milestones were booked but had not yet been paid out, so they were not yet cash in our bank.
And when we look closer at the net sales bridge.
We can see the net effect of the difference between the quarters here regarding the milestones in the innovative medicines column, which is fifty-nine million. Milestones, we can also see here that all other divisions developed positively, with the strongest growth in generics and consumer health. Tässä on operatiivisen voiton silta. We can see the full impact of the effects from previous years. Milestones reached one hundred and thirty million euros, with positive changes in sales volume, price adjustments, and cost of goods and product mix, overall. Twenty million and then the royalties of fifty million. We can also see that our fixed costs increased as well, but this is all planned. It is mainly our R&D and sales and marketing costs here. Now let's take a view for the first nine months from January to September again, a very nice twenty-two percent growth during the first nine months and seven point eight percent growth. Even though we compare to the previous year's quarter three including the milestones, the first three months end up with one point two billion of net sales, recording an operating profit of fifty-seven million, a fifty-seven percent growth, and slight decrease. If we compare to the numbers including milestones in the previous year, there was a very positive development in cash flow during the first nine months. Now to innovative medicines.
This is a bit of a different picture than you are used to seeing. There is the shaded area which tries to show you the comparison between the quarters, excluding everything else but the milestones from the previous year, and seventy-one percent growth is very healthy for innovative medicines.
Here you can see the all-time high royalties and product deliveries, totaling one hundred and sixty-six million, and I always remind looking at this picture.
The very. How do I say the year is very back-end loaded for Nubeqa. As you can see here when you look at the figures from the first quarter to the last quarter, but here as well, I would like to remind you that in comparison to the previous year. We already reached the higher royalty rate in the previous quarter with Nubeqa, so we are not going to see a similar shift and change in the royalty rate as we saw last year between Q3 and Q4. Branded products growth during Q3 was somewhat low. Kasvu oli kolme prosenttia, ja tämä kasvun hitaus johtuu pääasiassa toimitusten ajoituksesta Stalevo-kumppaneillemme, ja tämä korjataan loppuvuoden aikana. The product was the clear driver for the growth, and then in the CNS portfolio, Stalevo Japan contributed to growth in branded products. And as I say generics and Consumer Health's quarter. Three was very, very strong. Five point four percent growth is extremely good for any generic business, but especially here when we remember that Simdax and Dexdor are included in this business and they are constantly sliding down facing the generic competition. The service level is crucial in the generic business. You need to have the products available at the time of the tender where they should be, and you need to be able to deliver to all the different countries in their specific timing, often under specific pricing processes. Animal Health continued. The good growth trend continues here, although we see a bit of a similar slowdown as with branded products, and that partly has to do with deliveries as well. On the top ten product list, Nubeqa has been flagged as a key product with a growth of around three percent. Helppokäyttöisen inhalaattorituoteportfolion kasvu oli lähellä edellisvuotta, ja Entakaponi-tuotteen kasvu oli lähellä viittä prosenttia, pääasiassa Japanin myynnin ansiosta. Even though we are presenting growth close to their current state, our ABB products demonstrate growth, and currently, our business divisions are very healthy. The balance between business divisions is very healthy; approximately thirty percent for innovative medicines and generics, and close to twenty percent for branded products. Now Orion's clinical development pipeline has clearly become oncology-focused as we decided to discontinue the ODM-105 project for the treatment of insomnia.
We have also removed darolutamide from this list as it's approved both in the US and EU, so we now have the duscial hicap study on this list and then the two Omaha studies with Opevesostat that Emmes is responsible for, it is good to mention. In these two Opevesostat studies, the design and primary endpoints have changed since we last presented this, so that for the Omaha 3, which is for the later line patients.
The primary endpoint is now overall survival, so the progression-free survival has been demoted, and overall survival is the primary endpoint.
Also, there are changes for the frontline patients study. To this end, the progression-free survival is now a primary endpoint for this study.
These are changes that we made with our partner. MSD has done this, and it looks very logical in all possible ways.
Then we have the ACCES levosimendan study for pulmonary hypertension progressing in Phase 3, with plans to start another Phase 3 study by the end of this year. Another global study for this indication and then we have another study for Opevesostat for metastatic castration-resistant prostate cancer, as well as three phase two studies ongoing for several or three different women's hormonal cancers: breast, endometrial, and ovarian cancer. We have four solid tumors proceeding well in phase one, and we are preparing to start the phase two program in the first half of next year. Sitten viisi sanaa kestävyydestä.
This time, regarding decarbonization targets, we have set an ambitious target to reduce absolute scope 1 and 2 greenhouse gas emissions by seventy percent by the year 2030.
2030 and also have 78 percent of our suppliers.
Meaning scope three emissions. Tavoitteidemme piiriin kuuluu se. I think for Scope 1 and 2, we have very concrete actions ongoing. Steam production is one of the most energy-consuming phases in the chemical industry, especially in the API industry, and we are changing the energy source for steam production in all of our manufacturing facilities in Turku. We are electrifying the steam production in Oulu. We are changing to biofuels from fossil fuels, and we will also start an electrifying project in Espoo. Joten erittäin konkreettisia esimerkkejä täällä, ja olemme jo tehneet paljon konkreettisia toimia ja projekteja ennen tätä, esimerkiksi Honkon tehtaalla ja toimittajahallinnassa. We are targeting our highest emitting suppliers. We are not yet. Aligned with SBTi, we try to offer support and practices and technical expertise with our suppliers. Ja olemme tänään tarkentaneet näkymiämme. Our operating outlook for operating profit.
We have narrowed from four hundred ten to four hundred ninety million euros, so nothing drastic; we've been able to narrow it as the year has ten months already past.
There are two months left, and we have a much clearer view on how the year will pan out, especially regarding net sales. Our outlook is from 1,640 million to 1,720 million euros. And here you can see the upcoming events for next year, and I thank you on my behalf and welcome Rene here with me to answer your questions.